Disappointing Results Announced from Clinical Trial of Tysabri (Natalizumab) in Secondary-Progressiv

Summary • A phase III clinical trial of Tysabri® (natalizumab, Biogen) compared with placebo in 889 people with secondary-progressive MS did not meet its primary endpoint, meaning that Tysabri was not shown to slow progression using a combined measure of disability. • These results are reported in an October 21 press release from Biogen. Details of these results will be presented at a future medical meeting.

Background: Tysabri is a laboratory-produced monoclonal antibody that is approved for people with relapsing forms of MS to delay the accumulation of…

Favicon of www.nationalmssociety.org da : www.nationalmssociety.org

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati